Legal Costs and Jury Awards Batter Acadia Healthcare's Q2 Earnings as Revenue Stalls

summarizeSummary

Flat Q2 revenue and a steep drop in net income at Acadia Healthcare were driven by a $28.6M liability reserve charge and a $105M jury award against a subsidiary, while multiple legal and regulatory threats escalate.

check_boxKey Events · Earnings and Guidance · ACHC

• Q2 Earnings Miss

  Revenue came in flat year-over-year at $865.8M, while net income attributable to Acadia plunged to $10.9M, or $0.12 diluted EPS, from $30.1M, or $0.33, a year ago, as higher legal and insurance costs took a heavy toll.

• $105M Fashion Valley Jury Verdict

  A jury awarded $35M in compensatory and $70M in punitive damages against a subsidiary in an employment case. Although Acadia plans to appeal, the verdict far exceeds precedent and injects significant uncertainty into the liability outlook.

• $28.6M Liability Reserve Charge

  An unfavorable actuarial adjustment to self-insured professional and general liability reserves, reflecting higher expected settlement costs for prior-year claims, weighed on other operating expenses.

• Escalating Legal and Regulatory Threats

  A new securities class action (Kachrodia) saw its motion to dismiss denied on July 24, 2026. Meanwhile, DOJ and SEC investigations into admissions, length of stay, and billing practices remain ongoing.

auto_awesomeAnalysis · ACHC · Industrial Applications And Services

Acadia Healthcare's second-quarter results were overshadowed by a sharp drop in net income and a massive jury award against a subsidiary. Revenue was essentially flat year-over-year at $865.8 million, but net income attributable to Acadia fell to $10.9 million from $30.1 million a year ago. The bottom line was crushed by a $28.6 million unfavorable actuarial adjustment to self-insured liability reserves and a $105 million jury verdict (compensatory plus punitive) in the Fashion Valley employment case. While the company plans to appeal, the verdict creates significant uncertainty. On top of that, the 10-Q discloses a new securities class action (Kachrodia) where a motion to dismiss was denied just days ago, and ongoing DOJ and SEC investigations. The OBBBA legislation adds a regulatory overhang by capping Medicaid payment rates. The only bright spot: operating cash flow improved to $223.6 million, helped by insurance recoveries. The stock is likely to remain under pressure as legal liabilities mount.